← QL Research Library
WATCHAURALOW conviction · open✦ Commissioned

AURA at $7.125: Sell Consensus, Shallow Bearish Tape, and a 42%-Win Engine Buy — WATCH With Three Numbers

Published · entry price $7.125 · machine-generated by the QuantLogix Thesis Engine and graded publicly at T+7/30/90 days · AURA charts & signals →

AURA sits at $7.125 inside a fully conflicted stack: analysts say Sell with a $5.92 target (−16.9% implied downside), technicals are bearish but shallow, and the LIVE engine reads Buy at 62/100 with a calibrated win probability of just 42%. No side clears the +5% per-call bar — the name's Healthcare × engine-Buy cohort measures +2.99% over 272 signals with a judged month at −2.15%, and the long-side cohort is unverified. We publish WATCH with hard triggers at $8.00, $6.50, and $5.92; a verified long cohort or a reclaimed 20-day SMA would upgrade the call.

★ Follow this thesis Get notified as the position plays out — claim triggers, T+7/30/90 grades, and invalidation, by push and in-app. Pro members can also opt into email updates.
Convene grounded committee Re-underwrite this exact thesis against a frozen evidence packet — current price and signal with as-of timestamps, monitored claims, updates, and traceable sources. The committee cannot save an ungrounded verdict.

Options expression

IV rank 100 · expensiveImplied move ±37.8%
Neutral / watch verdict — options read only, no directional expression.
Paper marks at chain mids (last trade when the quote is absent) — the platform holds no option fills. Dealer positioning is assumed from open interest; flow side is the tape's tick-test inference or the snapshot contract side. Not investment advice. Whale Tape → · Dealer Flow → · Record + methodology →
Price claim ladder — entry vs monitored trigger levels
$6.5 · invalidates$5.92$8entry $7.125

Thesis

Evidence Graph2 of 4 claims linked · 3 preserved sources
Claim coverage2 / 4claims with evidence
Directional edges00 support · 0 challenge
Freshness3 / 3Latest dated source 08/30/2026
ConvictionLOW0 recorded changes

This graph uses only evidence frozen into the thesis at publication on 11/18/2026. “Retrieved source passage” is the preserved grounding excerpt the engine saw; “published note passage” is thesis context, not a source quote. Missing edges and dates remain visible.

C1Invalidation rule
0 linked sources

AURA holds above $6.50 through the T+30 grading window; a close below it falsifies the neutral-drift thesis.

No claim-level source relationship was preserved. Treat this as an open diligence item, not supporting evidence.
C2
0 linked sources

AURA does not close below the $5.92 consensus price target within 30 trading days.

No claim-level source relationship was preserved. Treat this as an open diligence item, not supporting evidence.
C3
2 linked sources

AURA closes above $8.00 within 30 trading days, confirming the LIVE engine's Buy read and arming a bullish upgrade.

S2Context matchQuantLogix coverageOpen source
quantlogix.ai
Published · quantlogix.ai

Legacy note context shares live, engine; support or opposition was not preserved.

Published note passage
Engine record. The LIVE Buy at 62/100 is mid-pack for the engine's healthcare coverage — its top conviction names scored 94 ([HRMY]) and 96 ([UTMD]).
S3Context matchQuantLogix coverageOpen source
quantlogix.ai
Published · quantlogix.ai

Legacy note context shares live, engine; support or opposition was not preserved.

Published note passage
Engine record. The LIVE Buy at 62/100 is mid-pack for the engine's healthcare coverage — its top conviction names scored 94 ([HRMY]) and 96 ([UTMD]).
C4
2 linked sources

AURA's 5-day momentum turns positive (above 0%) before the T+30 grading, as the first tape confirmation of the engine's 62/100 signal.

S2Context matchQuantLogix coverageOpen source
quantlogix.ai
Published · quantlogix.ai

Legacy note context shares 62, 100, engine; support or opposition was not preserved.

Published note passage
Engine record. The LIVE Buy at 62/100 is mid-pack for the engine's healthcare coverage — its top conviction names scored 94 ([HRMY]) and 96 ([UTMD]).
S3Context matchQuantLogix coverageOpen source
quantlogix.ai
Published · quantlogix.ai

Legacy note context shares 62, 100, engine; support or opposition was not preserved.

Published note passage
Engine record. The LIVE Buy at 62/100 is mid-pack for the engine's healthcare coverage — its top conviction names scored 94 ([HRMY]) and 96 ([UTMD]).

Unmapped source register

1 source

These links were preserved in the note but cannot be honestly assigned to a specific claim.

S1UnmappedQuantLogix coverageOpen source
quantlogix.ai
Published · quantlogix.ai
Published note passage
s (rates, cycle, sector rotation) is attached to this name on the platform, and I will not invent one; the cycle-relevant fact on the record is that the engine's own healthcare book judged −2.15% in 2026-08 (see the [QL Startup Daily…

What changed

Complete, timestamped thesis history.

Review in Thesis Lab →
  1. Thesis published
    WATCH · LOW conviction

Setup

This is user-requested initiation, not a model-driven screen pick, and the distinction matters: nothing in the request implies an edge, so the burden falls entirely on the tape. AURA prints at $7.125 inside a fully conflicted stack. Sell-side consensus is Sell with a $5.92 target; the technical tape is bearish but shallow; and the LIVE 5-factor engine reads Buy, 62/100, with a calibrated win probability of 42% — below a coin flip. One data-integrity flag before anything else: the quant context quotes the $5.92 target against a $6.34 reference price while the live print is $7.125. That anchor is stale, and the honest implied downside is −16.9% from live, not −6.6%. Under platform rules this note publishes as WATCH in any case — the Healthcare × engine-Buy cohort measures +2.99% over 272 signals, with a judged month at −2.15% (2026-08), below the +5% per-call alpha bar — so the only question is whether the evidence prices a side. It does not, and I will show why rather than hide behind the rule.

Evidence & Data

LayerReadingNote
Composite signalNeutral (−0.06)Flat
RSI / MACD45.2 / 0.051Neutral-soft; MACD barely positive
5d / 20d momentum−2.54% / −3.79%Mild deterioration
SMA trendBearishUnbroken
News sentiment0No informational edge
Analyst consensusSell, PT $5.92 (−16.9% vs live)Majority view
LIVE engineBuy, 62/100, win prob 42%Sub-coin-flip
Long cohort41.6% win, 406 signalsUnverified
Short cohort46.7% win, 892 signalsVerified but weak
Name cohort+2.99%, 272 signalsBelow +5% bar

Analyst consensus, explicitly weighed. The majority recommendation is Sell with a $5.92 target, −16.9% below the live print. I take it seriously as the market's anchor — but note the contradiction: a name trading 17% above its consensus target while news sentiment is exactly zero and options flow shows no large positioning or whale orders. Someone is wrong — either the target is stale momentum-extrapolation, or the price is complacent.

Technical stack, explicitly weighed. RSI 45.2 is neutral-soft, MACD 0.051 barely positive, 5d momentum −2.54%, 20d −3.79%, SMA trend bearish. The stack points down, but shallowly — a drift, not a breakdown, and it justifies no direction on its own.

News and macro, explicitly weighed. News sentiment is 0 — no edge. No live macro series (rates, cycle, sector rotation) is attached to this name on the platform, and I will not invent one; the cycle-relevant fact on the record is that the engine's own healthcare book judged −2.15% in 2026-08 (see the QL Startup Daily briefing, 08/30/2026), so defensive-sector rotation is not currently paying this cohort.

Engine record. The LIVE Buy at 62/100 is mid-pack for the engine's healthcare coverage — its top conviction names scored 94 (HRMY) and 96 (UTMD). Graded calibration says BEARISH calls have averaged −2.2% and BULLISH +1.7%, and bearish research running against LIVE reads like this one was right only 30% of the time. The pre-policy directional record is −2.06% over 41 calls — the +5% bar exists because of it.

Consensus vs. variant perception. The consensus view is Sell into −16.9% of downside. This thesis disagrees with the confidence on both sides, not necessarily the direction: the Sell case extrapolates a shallow dip while price sits far above target with zero news and zero flow; the engine's Buy carries a 42% win probability and an unverified long cohort (41.6% over 406 signals). What the market is missing is that the distribution is wide and unverified in both tails — and a wide, unverified distribution cannot clear a +5% per-call bar from $7.125. That refusal is the product.

Scenario Analysis

ScenarioProbabilityPrice pathThesis impact
Drift: shallow bearish tape persists, no news, no flow50%$7.125 → $7.00 (−1.8%)WATCH vindicated; cohort's +2.99% regime continues
Bear: Sell consensus validates, slide toward target30%$7.125 → $6.00 (−15.8%)$5.92–$6.00 zone tested; bearish trigger arms
Bull: engine Buy wins, 20d SMA reclaimed20%$7.125 → $8.00 (+12.3%)Bullish upgrade candidate only if long cohort verifies
Scenario probabilities — engine-assigned odds, price paths on hover
Drift: shallow bearish ta…50%Bear: Sell consensus vali…30%Bull: engine Buy wins, 20…20%

EV = 0.5×$7.00 + 0.3×$6.00 + 0.2×$8.00 = $6.90, −3.2% vs current $7.125 — negative carry on an unverified distribution, and nowhere near the +5% bar.

Catalysts & Risks

Catalysts: a reclaim of the 20-day SMA with 5d momentum flipping positive (MACD at 0.051 is one bad session from flipping); a cohort re-judgment lifting the Healthcare × Buy mean above +5% with no month ≤ 0; verification of the long cohort (currently 41.6%, unverified, 406 signals); any whale options positioning — the tape currently has none, so flow arriving would itself be news. Risks: a close under **$6.

What Changes Our Mind

The WATCH view on AURA is predicated on the current state of market ambiguity, where technicals are drifting and the engine's Buy signal is statistically unverified. We would pivot to a constructive Bullish stance if the stock achieves a sustained reclaim of the 20-day SMA accompanied by a clear positive shift in 5-day momentum, signaling a definitive breakout from the present malaise. Crucially, this move must be supported by a tangible increase in institutional flow or whale options positioning, which are currently non-existent.

Conversely, we would shift to an aggressive Bearish stance if AURA closes decisively below the $6.50 level. A breach of this support would invalidate the engine's current Buy probability, confirming that the Sell-side consensus target of $5.92 is not merely stale, but an emerging gravity well. Finally, a formal re-judgment of the Healthcare × Buy cohort showing consistent performance above our +5% alpha hurdle would be required to transform this signal from a passive observation into an actionable high-conviction trade. Until these specific triggers occur, the risk-reward remains insufficient to warrant a directional departure from our neutral posture.

Related QuantLogix coverage

More from QL Research

Share this research

Browse the full graded library →

QL Research is machine-generated educational market commentary, not investment advice. QuantLogix is not a registered investment adviser, broker-dealer, or financial planner. Theses, claims, verdicts, and grades are quantitative model outputs published for transparency and education; they are not recommendations to buy or sell any security. Markets involve substantial risk of loss. Past graded performance does not guarantee future results.